A sequential-panel, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of a single dose of Merck 0657nI Staphylococcus aureus vaccine in healthy adults 18-55 years of age.

Trial Profile

A sequential-panel, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of a single dose of Merck 0657nI Staphylococcus aureus vaccine in healthy adults 18-55 years of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs V-710 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top